Lead Product(s): Fadraciclib
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 20, 2020
The parties will assess Cyclacel’s fadraciclib and seliciclib , its clinical stage CDK2/9 inhibitors, for their suitability for use in safety and efficacy studies in COVID-19 patients.